The country’s apex drug regulator has asked states to enforce good manufacturing practices (GMP) in line with global standards, even in smaller companies, and initiate planning to carry out inspections of manufacturing units to confirm strict compliance with revised Schedule M.

However, no extension was granted on the December 2025 deadline, which many companies had sought.

In 2023, the Centre had notified revised Schedule M requirements wherein “good manufacturing practices” was upgraded to “good manufacturing practices and requirements of plan and equipment for pharmaceutical products”.

In his letter, Drugs Controller General of India (DCGI) Dr Rajiv Singh Raghuvanshi said, “…you are requested to initiate planning for carrying out relevant inspections of manufacturing units who have a

See Full Page